Opening Recap
Market Pulse: Precious metals ripped to fresh summits, with gold and silver storming record highs on word of Fed subpoenas, while crypto remains locked in a vice grip.
Key Movers: “Gold and Silver Storm to Records as Fed Hit With Subpoenas” (Yahoo Entertainment) roared to life, “Bitcoin compresses between $90K and $94K – A big move is brewing” (Ambcrypto.com) held firm, “BrainsWay Announces FDA Approval of Neurolief’s Proliv™Rx…” (GlobeNewswire) fired up health tech, and the U.K.’s approval of a triple-strength weight-loss shot (LADbible) jolted biotech.
Macro & Politics: Washington’s poking around the Fed’s playbook with subpoenas, and regulators from London to D.C. are flexing muscle—markets are feeling the heat.
What’s Next: Watch for nuggets at the J.P. Morgan Healthcare Conference, where Royalty Pharma and others could spark fresh biotech volatility.
Market Commentary
What everyone’s missing is that the subpoena bomb dropped on the Fed isn’t just political theater—it’s a trigger for a bloody short squeeze in bullion-backed ETFs and miner stocks. The “Gold and Silver Storm to Records as Fed Hit With Subpoenas” piece (Yahoo Entertainment) isn’t a sideshow; it’s a flashing warning that confidence in Fed policy is evaporating and traders are revolting in ounce denominations.
It sounds wild, but the same dynamic is at work in biotech: the U.K.’s go-ahead on a triple-strength GLP-1 shot (LADbible) and the FDA’s green light for Proliv™Rx (GlobeNewswire) show regulators can catapult market moves just as fast as subpoenas can. When you see weight-loss and neuromodulation stocks popping, don’t chalk it up to health fads—it’s the same power play that’s pushing gold parabolic.
If you’re still waiting on the sidelines, you’re going to miss the next leg: Bitcoin’s coiled in that compression highlighted in “Bitcoin compresses between $90K and $94K – A big move is brewing” (Ambcrypto.com) and poised to snap, and biotech titans at the J.P. Morgan Healthcare Conference will decide whether to extend the rally. Act before the herd storms in.
📈 Breaking Financial News
Millions with sleep apnea may soon have a simple pill-based treatment
Biotech firm Apnimed plans to seek FDA approval for its sleep apnea drug, with market availability expected by 2027
BrainsWay Announces FDA Approval of Neurolief’s Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)
BrainsWay’s strategic investment in Neurolief paved the way for the first and only FDA approved at-home neuromodulation device with Class III Premarket Approval labeling for MDD patients who failed one or more prior antidepressants
Metabo Drops 2026: Is It Legit? Ingredients, Safety Facts, and Consumer Analysis
Metabo Drops 2026: Is It Legit? Consumer analysis of coffee add-in supplements examines ingredients, safety disclosures, and evaluation criteria.
Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026
Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026
UK approves new dose of weight loss drug that's three times as powerful
The trials of the stronger Wegovy dose found weight losses of up to 25 percent
White House Insider Buck Sexton: “Trump's Next Move Will Shock the World” It cou
dramatically increase U.S. power… and trigger a massive American market boom the likes of which we haven't seen in 75 years. Get the details here now.
🔍 Market Analysis & Insights
Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on novel hematologic treatments, outlines achievements and 2026 objectives.
Profound Surpasses 2025 TULSA-PRO® Installed Base Goal
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) reports its TULSA-PRO installed base reached 78 systems, with a pipeline of 97 new systems.
Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio
Cogent Biosciences, Inc. (Nasdaq: COGT) outlines key 2026 milestones for its precision therapies targeting genetically defined diseases.
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
Royalty Pharma plc (Nasdaq: RPRX) previews its business performance and key accomplishments at the J.P. Morgan Healthcare Conference.
Bitcoin compresses between $90K and $94K – A big move is brewing
Bitfinex whales aggressively close long positions, a classic bullish signal for BTC.
Bitcoin In Serious Danger of Disappearing From Exchanges…
This could be the biggest “supply shock” in financial history! Bitcoin on exchanges is being bought up faster than miners can mine it. The smart money like BlackRock, Goldman Sachs, and MicroStrategy are doubling, tripling, quadrupling down. And they're doing everything they can to buy up ONE altcoin before prices blast-off like a Space X rocket. Discover the ONE altcoin smart money is buying up before Bitcoin's supply shock.
💰 Investment Opportunities
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
Launched KOMZIFTI™ (ziftomenib), the first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML, with preliminary revenue of $2.1 million.
Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand
Direct Meds reviews best GLP-1 weight loss shot prescription pathways for 2026 as oral semaglutide and injectable formats expand patient access.
ColonBroom GLP-1 Booster Ingredients Investigated: 2026 Consumer Analysis Examines Colon Broom GLP-1 Formulation Disclosures
ColonBroom GLP-1 Booster ingredient disclosure and formula transparency examined as January 2026 consumer metabolic supplement research continues.
Calm Nature CBD Gummies Ingredients: 2026 Consumer Analysis Examines Full Spectrum CBD Claims, Testing Standards, and Formulation Transparency
Consumer analysis examines Calm Nature CBD Gummies full spectrum formulation, CO2 extraction claims, COA availability, and 2026 transparency.
Gold and Silver Storm to Records as Fed Hit With Subpoenas
The yellow metal spiked above $4,600 an ounce, while silver surpassed $85 after Fed Chair Jerome Powell said the potential indictment comes amid “threats and…
Bitcoin In Serious Danger of Disappearing From Exchanges…
This could be the biggest “supply shock” in financial history! Bitcoin on exchanges is being bought up faster than miners can mine it. The smart money like BlackRock, Goldman Sachs, and MicroStrategy are doubling, tripling, quadrupling down. And they're doing everything they can to buy up ONE altcoin before prices blast-off like a Space X rocket. Discover the ONE altcoin smart money is buying up before Bitcoin's supply shock.
